IMV Inc IMV Stock News

IMV Inc (TSE: IMV) is making a run for the top in the market this morning, trading on gains of more than 30% early on. The gains come after the company announced advancements in the development of a vaccine for COVID-19. Here’s what’s happening:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

IMV Stock Pops On COVID-19 Update

In the press release, IMV said that it is advancing clinical development of a DPX-based vaccine candidate to fight COVID-19. Ultimately, the company is working to establish clinical safety and immunogenicity of a vaccine candidate based on its DPX delivery technology.

IMV said that it believes that its peptide-based approach, in combination with the portability of the DPX platform, offers key advantages.

The candidate, known as DPX-COVID-19 is being developed in collaboration with lead investigators for the Phase 1 study. These investigators include:

  • Joanne Langley, M.D. and Scott Halperin, M.D., of the Canadian Center for Vaccinology (CCfV) at Dalhousie University, the Izaak Walton Killam Health Center and the Nova Scotia Health Authority and the Canadian Immunization Research Network (CIRN);
  • along with Dr. Gary Kobinger, Ph.D., Director of the Research Centre on Infectious Diseases at the University Laval in Quebec City and Global Urgent and Advanced Research and Development (GUARD) in Canada.

In a statement, Dr. Langley had the following to offer:

As lead investigator on the Phase 1 study of DPX-RSV (Respiratory Syncytial Virus), I witnessed the unique potential of IMV’s epitope-based vaccine approach. I was particularly impressed by the persistence of immunogenicity at one year in an older adult population, suggesting that it is possible with this type of approach, to create an immune response that lasts for an extended period of time. I believe this collaboration creates the possibility of an accelerated path to clinical development of a vaccine to prevent COVID-19, and underscores the importance of public-private partnerships to tackle this epidemic.

The above statement was followed up by Frederic Ors, CEO at IMV. Here’s what he had to offer:

We appreciate the urgent need to find solutions to the growing pandemic. Across our many clinical studies, we have observed DPX technology to elicit a robust immune response with a sustained effect, including in sensitive populations. We believe this technology offers a meaningful solution as a potential vaccine, especially in older adults and those with pre-existing conditions who are most at risk to this virus and generally more difficult to vaccinate effectively. Additionally, we are pleased to be collaborating on this project with Dr. Langley, Dr. Halperin and Dr. Kobinger, who are leading voices in immunization and infectious disease and share our commitment to public health.

There Are Several Key Advantages Here

Ultimately, in the face of a pandemic like the coronavirus, a vaccine can prove to be overwhelmingly valuable. Although there is plenty of competition on the field, IMV has some key strategic advantages here.

First and foremost, the company’s peptide-based approach will likely lead to improved efficacy as this approach was designed for the development of vaccines far before the coronavirus plagued the earth.

Moreover, the company’s DPX platform is incredibly portable. The combination of these two advantages offers the potential for accelerated development as well as rapid-large scale production of the vaccine.

In times of a pandemic, speed is everything, and IMV has speed on its side. Considering this, the company is one that’s well worth watching closely.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Don’t Miss The Next Big Story

Join our free mailing list below to receive real-time news alerts!

Subscribe Today!

* indicates required


LEAVE A REPLY

Please enter your comment!
Please enter your name here

This site uses Akismet to reduce spam. Learn how your comment data is processed.